NasdaqGS:SVRABiotechs
Why Savara (SVRA) Is Up 5.4% After FDA Grants Priority Review To MOLBREEVI Application
Savara Inc. recently announced that the FDA has accepted for review its Biologics License Application for MOLBREEVI to treat autoimmune pulmonary alveolar proteinosis (autoimmune PAP) and granted the therapy Priority Review, with a PDUFA action date set for August 22, 2026.
The drug’s combination of Priority Review, Fast Track, Breakthrough Therapy, Orphan Drug, Innovation Passport, and Promising Innovative Medicine designations highlights both its potential clinical importance and the high...